Comparison of Two Treatment Regimens to Reduce PA Infection in Children With Cystic Fibrosis

PHASE2CompletedINTERVENTIONAL
Enrollment

304

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

June 30, 2009

Study Completion Date

August 31, 2009

Conditions
Cystic FibrosisPulmonary Disease, Chronic Obstructive
Interventions
DRUG

Tobramycin solution for inhalation (TOBI)

Tobramycin solution for inhalation, 300 mg, administered twice daily for 28 days administered only when quarterly respiratory cultures are found positive for Pa.

DRUG

Oral placebo

Oral placebo for six consecutive quarterly cycles. For the initial 14 days of the 28-day treatment period, the participants will receive placebo, twice daily.

DRUG

Oral ciprofloxacin

Oral ciprofloxacin for six consecutive quarterly cycles. For the initial 14 days of the 28-day treatment period, the participants will receive oral ciprofloxacin, 15-20 mg/kg/dose, twice daily.

Trial Locations (54)

10595

New York Medical College, Valhalla

12208

Albany Medical College, Albany

13210

State University of New York Upstate Medical University, Syracuse

14642

University of Rochester, Rochester

15213

Children's Hospital of Pittsburgh, Pittsburgh

17033

Penn State Milton S. Hershey Medical Center, Hershey

19803

duPont Hospital for Children, Wilmington

21287

Johns Hopkins University, Baltimore

22908

University of Virginia, Charlottesville

27599

University of North Carolina, Chapel Hill, Chapel Hill

30322

Emory University Cystic Fibrosis Center, Atlanta

30912

Medical College of Georgia, Augusta

32207

Nemours Children's Clinic, Jacksonville

33701

All Children's Hospital Cystic Fibrosis Center, St. Petersburg

35233

University of Alabama at Birmingham, Birmingham

38105

LeBonheur Children's Medical Center, Memphis

39216

University of Mississippi Medical Center, Jackson

43205

Children's Hospital, Columbus

44106

Rainbow Babies & Children's Hospital, Cleveland

44308

Children's Hospital Medical Center of Akron, Akron

45404

Children's Medical Center, Dayton

46202

Riley Hospital/Indiana University, Indianapolis

48201

Children's Hospital of Michigan, Detroit

49503

Spectrum Health Hospitals - DeVos Children's, Grand Rapids

52242

University of Iowa, Iowa City

53226

Children's Hospital of Wisconsin, Milwaukee

53792

University of Wisconsin Hospital and Clinics, Madison

55102

Children's Hospitals & Clinics, Minneapolis

60614

Children's Memorial Hospital, Chicago

63104

Cardinal Glennon Children's Hospital, St Louis

63110

Washington University School of Medicine, St Louis

64108

Children's Mercy Hospital, Kansas City

76104

Cook Children's Medical Center, Fort Worth

77030

Texas Children's Hospital, Houston

80045

Children's Hospital Denver, Aurora

84106

University of Utah, Salt Lake City

90027

Children's Hospital of Los Angeles, Los Angeles

94143

University of California, San Francisco, San Francisco

94611

Northern California Kaiser Cystic Fibrosis Center, Oakland

97239

Oregon Health Sciences University, Portland

98105

Children's Hospital & Regional Medical Center, Seattle

94304-5786

Stanford University, Palo Alto

40536-0284

University of Kentucky, Lexington

04102

Maine Medical Center, Portland

02114

Massachusetts General Hospital, Boston

02115

Children's Hospital, Boston, Boston

06155

University of Massachusetts Memorial Health Care, Worcester

48109-0212

University of Michigan, Ann Arbor

68198-5190

University of Nebraska, Omaha

03756-0001

Dartmouth-Hitchcock Medical Center, Lebanon

07740

Monmouth Medical Center, Long Branch

19134-1095

St. Christopher's Hospital for Children, Philadelphia

37232-9500

Vanderbilt University Medical Center, Nashville

05401

Vermont Children's Hospital at Fletcher Allen Health Care, Burlington

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

collaborator

Cystic Fibrosis Foundation

OTHER

collaborator

CF Therapeutics Development Network Coordinating Center

NETWORK

lead

Seattle Children's Hospital

OTHER

NCT00097773 - Comparison of Two Treatment Regimens to Reduce PA Infection in Children With Cystic Fibrosis | Biotech Hunter | Biotech Hunter